Steatosis and hepatitis C in an Alaska Native/American Indian population

References

• Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstål R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837–42.
   PubMed Web of Science ®Google Scholar
• Adinolfi L, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33 (6): 1358–63.
   PubMed Web of Science ®Google Scholar
• Hu K-Q, Kyulo N, Esrailian E, Thompson K, Chase R, Hillebrand D, Runyon B. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 2004; 40: 147–154.
   PubMed Web of Science ®Google Scholar
• Hezode C, Roudot-Thoraval F, Zafrani E-S, Dhumeaux D, Pawlotsky J-M. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004; 11: 455–8.
   PubMed Web of Science ®Google Scholar
• Cholet F, Nousbaum J-B, Richecoeur M et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol 2004; 28: 272–8.
   Google Scholar
• Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-26 and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38 (1): 75–85.
   Google Scholar
• Fartoux L, Poujol-Robert A, Guechot JH, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54 (7): 1003–8.
   Web of Science ®Google Scholar
• Asselah T, Boyer N, Guimont M-C et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003; 52: 1638–43.
   Google Scholar
• Sharma P, Balan V, Hernandez J et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors. Dig Dis and Sci 2004; 49 (1): 25–9.
   Google Scholar
• Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25 (3): 735–9.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Adinolfi L, Loria P, Carulli N, Ruggiero G, Day C. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586–597.
   PubMed Web of Science ®Google Scholar
• Bruden DL, McMahon BJ, Hennessy TW et al. Estimating the date of hepatitis C virus infection from patient interviews and antibody tests on stored sera. Am J Gastroenterol 2004; 99 (8): 1517–22.
   Web of Science ®Google Scholar
• Davidson F, Simmonds P, Ferguson J.C. et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol 1995; 76: 1197–204.
   Google Scholar
• Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–35.
   Google Scholar
• Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22 (6): 696–99.
   PubMed Web of Science ®Google Scholar
• Brunt EM, Janney CG, DiBisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic stestohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94 (9): 2467–74.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6): 1313–21.
   Google Scholar
• Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123–30.
   PubMed Web of Science ®Google Scholar
• Hui J, Kench J, Farrell G, Lin R, Samarasinghe D, Liddle C, Byth K, George J. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17: 873–81.
   PubMed Web of Science ®Google Scholar
• Castéla L, Hézode C, Roudot-Thoraval F et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288–92.
   Google Scholar
• Hofer H, Bankl HC, Wrba F et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroentero 2002; 97 (11): 2880–85.
   Google Scholar
• Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.J Hepatol 2000; 33: 106–15.
   Web of Science ®Google Scholar
• Yoon EJ, Hu K-Q. Hepatitis C (HCV) infection and hepatitic steatosis. Int J Med Sci 2006: 3: 53–56.
   PubMedGoogle Scholar
• Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006; 13: 73–80.
   PubMed Web of Science ®Google Scholar
• Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus gentype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36 (5): 1266–1272.
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, McHutchison, Manns M, Goodman Z, Zeuzem S et al. Effect of treatment with peginterferon or interferon alfa-26 and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38 (1): 75–85.
   Google Scholar
• National Institutes of Health consensus development conference statement: Management of hepatitis C. Hepatology 2002; 36: S3–S20.
   Google Scholar
• Strader DB, Wright T, Thomas DL, Seef LB. AASLD Practice Guideline: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39 (4): 1147–71.
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Hennessy TW, Christensen C et al. Epidemiology and risk factors for hepatitis in Alaska Natives. Hepatology 2004; 39 (2): 325–32.
   Web of Science ®Google Scholar
• Armstrong GL, Simard EP, Wasley A, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus (HCV) infection in the United States, 1999–2002. Hepatology 2004; 40 (4) Suppl.1:176A.
   Google Scholar